<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03129724</url>
  </required_header>
  <id_info>
    <org_study_id>6154</org_study_id>
    <nct_id>NCT03129724</nct_id>
  </id_info>
  <brief_title>Retrospective Study in Patients With Metastatic Renal Cancer Treated With TKI Sequence (Tyrosine Kinase Inhibitors of VEGFR) - mTOR- Axitinib Inhibitors or Anti-VEGF Antibody -Inhibiteurs mTOR - Axitinib</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Strasbourg, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Strasbourg, France</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Describe in patients with metastatic kidney cancer treatment modalities with the type
      sequences: TKI - mTORi - Axitinib or VEGF mAb - mTORi - Axitinib.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>September 2016</start_date>
  <completion_date type="Anticipated">July 2017</completion_date>
  <primary_completion_date type="Anticipated">July 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Evolution of Kidney cancer</measure>
    <time_frame>after surgery, up to 1 year]</time_frame>
  </primary_outcome>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Kidney Neoplasms</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patient with metastatic kidney cancer (all histological types) Patient has been treated or
        under treatment with axitinib (Inlyta®) in the third line after the first line of targeted
        TKI therapy and after mTORi in 2nd line, or Patient receiving the treatment sequence
        VEGFmAb - mTORi - axitinib
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Patient with metastatic kidney cancer (all histological types)

          -  Male or female aged (e) of 18 or more

          -  Patient has been treated or under treatment with axitinib (Inlyta®) in the third line
             after the first line of targeted TKI therapy and after mTORi in 2nd line, or

          -  Patient receiving the treatment sequence VEGFmAb - mTORi - axitinib For living
             patients: patient informed and having given oral consent

        Exclusion criteria:

          -  Patient who received more than one line of antiangiogenic therapy in the metastatic
             phase before initiation of treatment with axitinib (except patients in the study
             Pisces) Patient received a second line treatment with TKI Patient refused to
             participate in the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Philippe Barthélémy, MD</last_name>
    <phone>33 3 88 11 58 77</phone>
    <email>philippe.barthelemy@chru-strasbourg.fr</email>
  </overall_contact>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 5, 2016</study_first_submitted>
  <study_first_submitted_qc>April 21, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 26, 2017</study_first_posted>
  <last_update_submitted>April 21, 2017</last_update_submitted>
  <last_update_submitted_qc>April 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 26, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Kidney Neoplasms</keyword>
  <keyword>Kidney</keyword>
  <keyword>Neoplasms</keyword>
  <keyword>TKI</keyword>
  <keyword>Axitinib</keyword>
  <keyword>VEGF</keyword>
  <keyword>mTORi</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Kidney Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Axitinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

